Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK-positive Advanced Tumors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT05441956
What this trial is testing

TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
Shenzhen TargetRx Co., Ltd. 198
Testing effectiveness (Phase 2)Study completedNCT01562015
What this trial is testing

Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung Cancer
Synta Pharmaceuticals Corp. 12
Post-approval studies (Phase 4)Not Yet RecruitingNCT07671560
What this trial is testing

Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC

Who this might be right for
ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib
Qiming Wang 80
Large-scale testing (Phase 3)Active Not RecruitingNCT06569420
What this trial is testing

Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC

Who this might be right for
Non-Small Cell Lung CancerALK-positiveSAF-189s
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 275
Not applicableStudy completedNCT04947683
What this trial is testing

Patient Journey With Advanced Lung Cancer Positive for ALK Fusion in Brazil

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Latin American Cooperative Oncology Group 101
Testing effectiveness (Phase 2)UnknownNCT04237805
What this trial is testing

A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Advanced CancerAdvanced Solid TumorLung Cancer, Nonsmall Cell
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 280
Not applicableUnknownNCT05132218
What this trial is testing

Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer

Who this might be right for
ALK PositiveNSCLC Stage IIIBNSCLC Stage IV
Peking University Cancer Hospital & Institute 180
Testing effectiveness (Phase 2)WithdrawnNCT03868423
What this trial is testing

Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

Who this might be right for
Advanced Malignant NeoplasmALK Fusion Protein ExpressionALK Gene Amplification+8 more
Sameek Roychowdhury
Testing effectiveness (Phase 2)Looking for participantsNCT07415005
What this trial is testing

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Study completedNCT02040870
What this trial is testing

LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 103
Not applicableNot Yet RecruitingNCT06652555
What this trial is testing

The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study

Who this might be right for
ALKNSCLC
Shanghai Pulmonary Hospital, Shanghai, China 100
Early research (Phase 1)Study completedNCT02422589
What this trial is testing

A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors

Who this might be right for
ALK-positive Advanced Tumors
Novartis Pharmaceuticals 33
Not applicableLooking for participantsNCT07696832
What this trial is testing

Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study

Who this might be right for
Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLCEGFR Mutation-negative and ALK Rearrangement-negativeEastern Cooperative Oncology Group Performance Status (ECOG PS) Score of 0 to 2+2 more
Guangdong Association of Clinical Trials
Early research (Phase 1)Looking for participantsNCT07784959
What this trial is testing

Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

Who this might be right for
ALK PositiveALK Positive Non-small Cell Lung CancerNSCLC+1 more
Nuvectis Pharma, Inc. 54
Not applicableStudy completedNCT06339554
What this trial is testing

Alectinib-induced Endocrine Toxicity

Who this might be right for
NSCLC Stage IV
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 98
Large-scale testing (Phase 3)UnknownNCT05204628
What this trial is testing

Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib

Who this might be right for
Non-small Cell Lung Cancer
Xuanzhu Biopharmaceutical Co., Ltd. 238
Testing effectiveness (Phase 2)Study completedNCT01945021
What this trial is testing

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

Who this might be right for
Non Small Cell Lung CancerROS1 Proto OncogeneCrizotinib
Pfizer 129
Testing effectiveness (Phase 2)UnknownNCT04425135
What this trial is testing

Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC

Who this might be right for
Lung Neoplasms
The First Affiliated Hospital of Xiamen University 59
Testing effectiveness (Phase 2)Study completedNCT04111705
What this trial is testing

Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer Metastatic
Intergroupe Francophone de Cancerologie Thoracique 23
Post-approval studies (Phase 4)Not Yet RecruitingNCT06785584
What this trial is testing

Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study

Who this might be right for
ALK-positive Advanced NSCLCALK-positive Non-small Cell Lung Cancer (NSCLC)MPR+1 more
Fujian Medical University Union Hospital 30
Next Page
265